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Background: Parkinson’s disease (PD) is characterized by loss of dopaminergic neurons
and intraneuronal accumulation of alpha-synuclein, both in the basal ganglia and in
peripheral sites, such as the gut. Peripheral immune activation and reactive oxygen
species (ROS) production are important pathogenetic features of PD. In this context,
the present study focused on the assessment of in vitro effects of probiotic bacterial
strains in PBMCs isolated from PD patients vs. healthy controls.
Methods: 40 PD patients and 40 matched controls have been enrolled. Peripheral
blood mononuclear cells (PBMCs) were isolated and co-cultured with a selection of
probiotics microorganisms belonging to the lactobacillus and bifidobacterium genus. In
vitro release of the major pro- (Tumor Necrosis Factor-alpha and Interleukin-17A and
6) and anti-inflammatory (Interleukin 4 and 10) cytokines by PBMCs, as well as the
production of ROS was investigated. Furthermore, we assessed the ability of probiotics
to influence membrane integrity, antagonize the growth of potential pathogen bacteria,
such as Escherichia coli and Klebsiella pneumoniae and encode tyrosine decarboxylase
genes (tdc).
Results: All probiotic strains were able to inhibit inflammatory cytokines and ROS
production in both patients and controls. The most striking results were obtained in
PD subjects with L. salivarius LS01 and L. acidophilus which significantly reduced pro-
inflammatory and increased the anti-inflammatory cytokines (p < 0.05). Furthermore,
most strains determined restoration of membrane integrity and inhibition of E. coli and
K. pneumoniae. Finally, we also showed that all the strains do not carry tdc gene, which
is known to decrease levodopa bioavailability in PD patients under treatment.
Conclusions: Probiotics exert promising in vitro results in decreasing pro-inflammatory
cytokines, oxidative stress and potentially pathogenic bacterial overgrowth. In vivo
longitudinal data are mandatory to support the use of bacteriotherapy in PD.
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INTRODUCTION
Parkinson’s disease (PD) is a common neurodegenerative disease,
characterized by loss of dopaminergic neurons and intracellular
accumulation of alpha-synuclein (α-syn) in the surviving
neurons (1). Involvement of inflammatory mechanisms, with
an imbalance between detrimental and protective immune
functions (2), as well as neurotoxicity of reactive oxygen species
(ROS) have been documented by several studies (3, 4). Both
neuroinflammation and ROS may favor α-syn aggregation which
may in turn increase pro-inflammatory cytokines and oxidative
stress, thus triggering a vicious circle (5). Clinical presentation
of PD is classically defined by the presence of motor symptoms
such as bradykinesia, rest tremor, and rigidity. On the other
hand, patients often complain of non-motor symptoms like
hyposmia, constipation, pain and psychiatric conditions (e.g.,
anxiety, depression) that in many cases may precede the onset
of clinically established disease (6, 7). Seminal work by Braak
et al. hypothesized an initial aggregation of α-syn in the gut with
subsequent propagation along the vagus nerve to the brain to
reach the substantia nigra in the mesencephalon (8). Moreover,
constipation represents a relevant symptom of PD, affecting
about 70–80% of patients (9) and may precede motor symptoms
by 20 years (10). The loss of enteric dopaminergic neurons
determines an impairment of gastric mobility with an increased
dopaminergic content and overexpression of dopaminergic
receptors in the stomach (11). Furthermore, PD patients present
an increased intestinal permeability and higher expression of
colonic pro-inflammatory cytokines (12). Accordingly, in an
α-syn overexpressing murine model of PD, gut microbiota is
necessary for both microglia activation and motor impairment
(13). In addition, a direct correlation between gut bacterial count
and disease progression was found in PD patients (14). PD
patients have a different composition of gutmicrobiota compared
to healthy subjects (15) with reduced levels of Prevotellaceae
and abundance of Enterobacteriaceae (16). Prevotella are in fact
involved in the production of thiamine and folate, both of
which are important for proper intestinal homeostasis (17). On
the contrary, increased levels of Enterobacteriaceae have been
associated to a severe PD phenotype with postural instability and
gait difficulty. (16).
Of note, there is evidence that probiotics may modulate
not only inflammation through cytokines production (18, 19),
but also oxidative damage through a down-modulation of ROS
(20). Another relevant aspect of the host-microbial interaction
is the established role of infections in accelerating clinical
decline in PD patients (21). In a recent investigation, focused
on the clinical features and therapeutic outcomes of infected
patients with or without PD, the incidence of respiratory tract
and urinary tract infections was higher in PD than in age
and sex-matched non-PD patients. Additionally, a longer mean
hospitalization time was observed in the PD group (22). In
this regard, specific probiotic strains may potentially counteract
the growth of common pathogens, such as Escherichia coli
(E. coli) and Klebsiella pneumoniae (K. pneumoniae) (23, 24).
Furthermore, Van Kessel et al. recently reported that some
probiotic strains produce tyrosine decarboxylase (TDC) (25).
This bacterial enzyme efficiently converts levodopa to dopamine
in the gut, even in the presence of human decarboxylase
inhibitors or tyrosine, a competitive substrate. Accordingly, in
situ levels of levodopa in PD patients are decreased by significant
abundance of gut bacterial TDC (25). TDC genes (tdc) have
been detected in particular in the genome of numerous bacterial
species within the genera Lactobacillus and Enterococcus (26, 27).
Abundance of bacterial tdc in stool specimens of PD patients
was indeed correlated with increased daily dosage requirement
of levodopa (25).
On this background, the aim of our study was to investigate
the in vitro effects of probiotics on samples from a group of PD
patients compared to healthy subjects. To do that, we assessed
cytokine and reactive oxygen species (ROS) release by peripheral
blood mononuclear cells (PBMCs), and restoration of artificial
membrane permeability. In addition, we investigated the ability
of the selected probiotics to directly inhibit E. coli and K.
pneumoniae. Finally, we verified the absence of tdc within the
genome of the selected probiotic strains.
PATIENTS AND METHODS
Patients
We enrolled 40 patients with PD (15 women and 25 men, mean
age 70 ± 8 years) and 40 age-matched healthy donors (HD, 18
women and 22 men, mean age 68 ± 7 years). PD diagnosis
was performed according to the Movement Disorders Society
(MDS) diagnostic criteria, e.g., when: (a) subjects presented with
a parkinsonism, defined as bradykinesia, associated to rest tremor
or rigidity without signs of atypical parkinsonism; (b) exclusion
criteria, red flags and supportive criteria were assessed (28).
Patients were regularly followed-up at the Movement
Disorder Center of Maggiore Hospital in Novara (Italy). For each
patient the following parameters were considered: gender, age at
onset, disease duration, Hoehn & Yahr stage (29), UPDRS III
score (30), and PD therapy calculating the levodopa equivalent
doses (LED) of each drug according to Tomlinson et al. (31).
Subjects with past or concomitant autoimmune disease and
with a previous or ongoing immune-modulating or suppressive
therapy were excluded. All subjects underwent a complete
blood cell (CBC) analysis including C-Reactive Protein (CRP)
and erythrocyte sedimentation rate in order to exclude both
defects or activation of the immune system. All subjects were of
Italian origin.
This study was approved by the local Ethics Committee (CE
65/16). Patients were included in the study after having read and
signed an informed consent form for research purpose.
Cell Cultures
Twenty milliliters of blood were drawn by venipuncture in
vacuum tubes containing heparin on the same day of the clinical
assessment. In order to rule out any confounding factors caused
by circadian rhythm, all samples were collected at the same time
of the day. Human PBMCs were isolated from heparinized blood
by Healthy Donors (HD-PBMCs) and PD patients (PD-PBMCs).
For cell isolation, standard techniques of dextran sedimentation
and Histopaque (density = 1.077 g/cm3) gradient centrifugation
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(400 × g, 30min, room temperature) were used. Cells were then
recovered by thin suction at the interface. Isolated cells were then
re-suspended in RPMI 1640medium supplemented with 5% fetal
bovine serum (FBS) and 2mM glutamine. Cell viability (trypan
blue dye exclusion) was usually >98%.
Bacteria and Growth Conditions
Six probiotic strains (Lactobacillus salivarius LS01 DSM 22775,
Lactobacillus plantarum LP01 LMG P-21021, Lactobacillus
acidophilus LA02 DSM 21717, Lactobacillus rhamnosus LR06
DSM 21981, Bifidobacterium animalis subsp. lactis BS01 LMG
P-21384, Bifidobacterium breve BR03 DSM 16604), from the
Probiotical SpA collection, have been used in the present
study: probiotic strains were stored in 20% glycerol at −80◦C.
More than 90% of the cells were alive upon thawing. Before
use, microorganisms were grown in anaerobic conditions
with CO2-generating kits (Anaerocult A; Merck, Darmstadt,
Germany) overnight at 37◦C in de Man-Rogosa-Sharpe (MRS)
broth containing 0.05% cysteine hydrochloride, and then
sub-cultured until the mid-log phase. For the enumeration
of live bacteria, the BD Cell Viability Kit (BD Biosciences,
Milan, Italy) were used as instructed by the manufacturer.
For stimulation experiments, bacteria were suspended
in RPMI-1640 medium [Invitrogen, Italy] and added to
PBMCs cultures.
Cytokine Release
Cytokine release by PBMCs was measured with an enzyme-
linked immunoassay kit according to the manufacturer’s
instructions (ELISA Ready-SET-Go! Affymetrix eBioscience,
USA). Interleukin 17A (IL-17A), tumor necrosis factor α (TNF-
α), and IL-10 were assessed in both healthy controls and PD
patients, whereas IL-6 and IL-4 were assessed only in PD-
PBMCs (before and after probiotic stimulation). The levels of
each cytokine were calculated in ρg/ml, in accordance with the
manufacturer’s instructions. For these experiments, HD and PD
PBMCs (1 × 106 cells/plate) were pre-treated for 24 h with the
indicated probiotic strains in 1:1 ratio. Only HD PBMCs were
treated previously with purified lipopolysaccharide (LPS) from E.
coli 055:B5 (Sigma Chemicals, Milan, Italy) at a concentration of
10 g/mL.
Superoxide Anion (O−2 ) Production
HD- and PD-PBMCs (1 × 106 cells/plate) were treated for
24 h with probiotic strains in 1:1 ratio. O−2 production was
evaluated by the superoxide dismutase-sensitive cytochrome C
reduction assay and calculated as nmol reduced cytochrome
C/106 cells/30min, using an extinction coefficient of 21.1mM.
To avoid interference with spectrophotometrical recordings, cells
were incubated with RPMI 1,640 without phenol red and FBS.
Basal values (O−2 production from unstimulated PBMCs) in HD
were 2.2 ± 0.4 nmol reduced cytochrome C/106 cells/30’, and in
PD patient-PBMCs were 140 ± 12 nmol reduced cytochrome
C/106 cells/30’. PMA is a stimulus known to induce a strong
and significant respiratory burst. In line with this, PMA 10−7
M exposure determined a significant increase of cytochrome
C levels in HD-PBMCs: 52 ± 4.5 nmol reduced cytochrome
C/106 cells/30′.
Measurements of TransEpithelial Electrical
Resistance (TEER)
Caco-2 cells are human colonic adenocarcinoma cells that
form confluent, polarized epithelial monolayers with well-
differentiated intercellular tight junctions structures. The
integrity of the barrier function can be measured with
TransEpithelial Electrical Resistance (TEER). TEER is an
in vitro measurement of the movement of ions across the
paracellular pathway.
A reduction in TEER may represent an early expression
of cell damage and indicates that the barrier function of the
intestine is decreased. Caco-2 cell lines have been extensively
used over the last 20 years as a model of the intestinal
barrier. The experiment was performed with an inflammatory
stressor (a combination of TNF-α and IL1-ß), which is known
to reduce the relative TEER of Caco-2 cells. The monolayer
of Caco-2 cells was first exposed to the probiotic bacteria
for 1 h, followed by exposure to the inflammatory stressor
in the presence of the same probiotic bacteria, also for 1 h.
After a recovery time of 24 h the TEER of the monolayer
was measured. The results were compared to the TEER of a
monolayer that was exposed to the stressor alone and to an
unexposed sample. Cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% fetal bovine serum. Caco-
2 (1 × 106 cells/well) differentiated at 20 days were provided
by the Anemocyte s.r.l. (Gerenzano, Varese, Italy). TEER
was measured in each monolayer before adding 106 AFU
[Active Fluorescent Units were evaluated with cytofluorimetric
analytical method ISO 19344:2015 (E)-IDF 232:2015 (E)] of
probiotic strains onto the apical surface for 24 h prior to
treatment of the basolateral medium with TNF-α and IL1-
ß (10 ng/ml; Thermo Scientific, USA). It was determined that
106 AFU of probiotic strains did not cause deleterious effects
on epithelial cells over the time-course of the experiments
and that the medium used in this experiment did not cause
bacterial overgrowth.
Spot-on Lawn Antimicrobial Assay/Agar
Spot Antimicrobial Assay
The antimicrobial activity against E. coli and K. pneumoniae
was assessed according to the protocol described by Santini C.
(32). Briefly, 5 µl of probiotic overnight fresh cultures with an
optical density (OD) at 600 nm close to 1 were spotted on the
surface of MRS agar plates and incubated anaerobically for 5 h
at 37◦C to allow strain development (spot). The E. coli ATCC
8739 strain or K. pneumoniae ATCC 13883 strain was inoculated
in Brain Heart Infusion (BHI) soft agar and dispensed onto spot
plates. When the top agar was solid, the plates were inverted and
incubated in conditions of anaerobiosis at 37◦C for 48 h. At the
end of incubation, plates were examined for the appearance of
clear zones showing the antagonistic activity. The plate inhibition
technique experiments were carried out on triplicates, and the
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TABLE 1 | Modulation of cytokines production by the probiotic strains in PD patients.
Probiotic strain IL10 TNF-α IL17-A IL4 IL6
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
LS01 Baseline 140.12 18.01 255.52 29.55 114.08 15.41 102.00 16.4 197.2 18.2
After stimulus 194.24 15.42 146.69 28.67 52.48 9.25 149.6 34.7 135.2 4.2
P <0.001 <0.001 <0.001 <0.01 <0.001
LP01 Baseline 121.81 20.17 221.80 16.18 120.04 16.00 110.2 12.3 178.2 22.8
After stimulus 161.70 20.17 264.10 100.41 73.22 11.32 135.2 21.3 114.9 11.4
P <0.001 0.01 <0.001 n.s. 0.01
LA02 Baseline 165.33 20.53 228.90 26.89 112.81 15.28 26.3 2.5 180.2 18.2
After stimulus 192.18 23.22 195.15 33.52 87.99 12.80 45.6 4.9 92.5 5.9
P <0.001 <0.001 <0.001 <0.05 <0.001
LR06 Baseline 196.71 23.67 128.90 16.89 112.81 15.28 60.00 1.15 188.0 22.30
After stimulus 241.63 18.16 123.54 46.35 81.22 12.12 88.2 21.1 112.5 11.4
P <0.001 n.s <0.001 <0.05 <0.001
BS01 Baseline 186.71 22.67 255.74 29.57 119.44 15.94 71.2 15.3 196.4 29.6
After stimulus 236.34 33.63 297.82 38.78 109.88 14.99 99.2 22.4 96.3 21.4
P <0.001 <0.001 0.007 n.s <0.001
BR03 Baseline 141.12 18.11 117.19 15.72 116.43 15.64 110.7 18.11 190.8 16.7
After stimulus 147.38 17.74 82.30 13.14 72.19 11.22 147.38 18.7 81.9 18.1
P n.s. <0.001 <0.001 <0.05 <0.001
All data are expressed in pg/ml; n.s., not statistically significant.
FIGURE 1 | Modulation of cytokine production by probiotic strains. For each probiotic strain the first column indicates the baseline values, while the second after
probiotic administration. *p < 0.001; #p < 0.05 post vs. pre-exposure from PD-PBMCs.
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mean values of growth inhibition zones around the disks were
measured using a ruler (mm) and recorded.
Search for Tyrosine Decarboxylase (TDC)
Genes
To identify whether the genomes of the probiotic strains
employed encoded tdc, the TDC protein sequence (EOT87933)
from Enterococcus faecalis v583 was used as a query along with
E. faecalis v583 as a positive control using the BLAST program
of PATRIC suite (www.patricbrc.org). E. faecalis V583 TDC
protein sequence (NCBI accession: EOT87933) was downloaded
in FASTA format. PATRIC suite was used for the Annotation of
the six bacterial strains using the RAST tool kit encoded within
the software. Annotated genomes were grouped together and
BLASTed against the TDC protein sequences.
Statistical Analysis
Results are expressed as the means± SEM of duplicate measures
determined in three independent experiments. Differences
between unstimulated and stimulated samples were tested using
the t test with GraphPad Prism 6.0 software. Correlations
between probiotic strain and clinical-demographic variables
were calculated using Spearman test. Values of p < 0.05 were
considered significant.
RESULTS
Cytokine Release
IL-10 and IL-4 are important cytokines in the regulation
of immune responses, counterbalancing the pro-inflammatory
effects of TNF-α, IL-6 and IL-17A. Cytokines modulation
by different probiotic strains was measured in PBMCs from
both PD patients and healthy donors (Table 1 and Figure 1;
Table S1). In PD-PBMCs, most probiotic strains determined a
statistically significant reduction of pro-inflammatory cytokines
production (TNF-α, IL-6, and IL-17A) and an increase of the
anti-inflammatory IL-4 and IL-10. The most striking results were
obtained with LS01 (TNF-α: baseline 255.52± 29.55 pg/ml, after
stimulus 146.69 ± 28.67 pg/ml, p < 0.001; IL-6 baseline 197.2 ±
18.2 pg/ml, after stimulus 132.5 ± 4.2 pg/ml, p < 0.001; IL17-A
baseline 114.08± 15.41 pg/ml, after stimulus 52.48± 9.25 pg/ml,
p < 0.001; IL-4 baseline 102.00 ± 16.4 pg/ml, after stimulus
149.6 ± 34.7 pg/ml, p < 0.001; IL-10: baseline 140.12 ± 18.01
pg/ml, after stimulus 194.24± 15.42 pg/ml, p < 0.001) and LA02
(TNF-α: baseline 228.90 ± 26.89 pg/ml, after stimulus 195.15 ±
33.52 pg/ml, p < 0.001; IL-6 baseline 180.2 ± 92.5 pg/ml, after
stimulus 92.5 ± 5.9 pg/ml, p < 0.001; IL17-A baseline 112.81 ±
15.28 pg/ml, after stimulus 87.99 ± 12.80 pg/ml, p < 0.001; IL-4
baseline 26.3 ± 2.5 pg/ml, after stimulus 45.6 ± 4.9 pg/ml, p <
0.05; IL-10: baseline 165.33 ± 20.53 pg/ml, after stimulus 192.18
± 23.22 pg/ml, p < 0.001). The remaining data, including all p
values, are shown in Table 1.
Superoxide Anion (O−2 ) Production
First, we found a statistically significant difference in baseline
O2− production from unstimulated PBMCs between patients
and controls. In fact, reduced cytochrome C in HD was 2.2
± 0.4 nmol vs. 140 ± 12 nmol/106 cells/30’ in PD-PBMCs (p
< 0.001). To test the antioxidant effects of probiotics on HD-
PBMCs we induced a toxic condition using PMA, a stimulus
known to determine a strong and significant respiratory burst.
Consistently, PMA exposure in HD-PBMCs increased levels of
FIGURE 2 | Reduction of superoxide anion (O−2 ) production. *p < 0.01 post vs. pre-exposure from PD-PBMCs. #p < 0.05 post vs. pre-exposure from PMA-exposed
HD-PBMCs.
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TABLE 2 | TERR evaluation using different probiotic strains.
LA02 LP01 LR06 LS01 BR03 BS01
Baseline integrity 100% 100% 100% 100% 100% 100%
Integrity after
damaging stimulus
40% 40% 40% 40% 40% 40%
Integrity after
probiotic strain
91% 100% 100% 81% 94% 84%
P value <0.05 <0.001 <0.001 <0.05 <0.05 <0.001
TABLE 3 | Inhibition of bacterial overgrowth exerted by probiotic strains.
Probiotic strain [inhibition (mm)] E. coli K. pneumoniae
Mean SEM Mean SEM
LS01 0.43 0.15 0.58 0.17
LP01 0.57 0.14 1.42 0.56
LA02 0.30 0.11 0.23 0.10
LR06 0.48 0.10 0.63 0.37
BS01 0.01 0.004 0.11 0.05
BR03 0.01 0.004 0.15 0.01
Results are expressed in mm.
reduced cytochrome c (52 ± 4.5 nmol). As depicted in Figure 2,
after exposure to probiotic strains, we found an overall decrease
of O−2 production in unstimulated PBMCs from PD patients
and in PMA-stimulated PBMCs from HD. In detail, LS01, LP01,
LA02, LR06, BS01 caused a robust decrease of O−2 from PD-
PBMCs (p < 0.01 post vs. pre-exposure). A weaker, though
statistically significant, effect was obtained from PMA-stimulated
HD-PBMCs after exposure to LS01, LP01, BR03 (p < 0.05 post
vs. pre-exposure).
TEER Evaluation
Three strains (LP01, LR06, and BR03) provided higher
protection of epithelial cells against the cytokine-induced barrier
dysfunction (p < 0.001), whereas three others (LS01, LA02, and
BS01) had a lower, though still significant, effect (p < 0.05). The
TEER ratio was measured before adding the bacterial inoculum
(CTR) and in a damage-tissue model and after addition and
incubation of the probiotic strains on Caco-2 monolayer. The
results are shown in Table 2 and Figure S1.
Inhibition of E. coli and K. pneumoniae
As shown in Table 3, most probiotic strains showed a robust
inhibitory capacity against the target pathogen strains E. coli and
K. pneumoniae involved in the comorbidities of PD. Particularly,
LP01 and LR06 exerted the highest inhibition. Moreover, such
inhibition was not observed when a negative control (MRS
acidified at pH 4.3 but without any probiotic strains; data not
shown) was tested, thus confirming the specificity of the detected
antagonistic activity.
TABLE 4 | Comparison of ROS production after each probiotic stimulation
between female and male patients.
LA02 LP01 LR06 LS01 BR03 BS01
Female 0.29 0.16 0.40 0.06 0.82 0.16
Male 0.20 0.14 0.19 0.06 0.83 0.31
p value 0.17 0.67 0.005 0.97 0.97 0.03
Data are expressed as the value after probiotic strain exposure from a baseline
conventionally established as 1. The statistically significant differences are shown in bold.
Tyrosine Decarboxylase (TDC) Genes
Only E. faecalis V583 gave an Identity value equal to 100% with
a Query Cover of 100%, whilst the other probiotic strains scored
below 35% of Identity, thus excluding the expression of a tyrosine
decarboxylase activity within the six tested probiotic strains (data
not shown).
Clinical Analysis
Demographic Results
Mean age at PD onset was 65 ± 8 years. In detail, at study
enrollment, 4 patients were drug naïve, 26 were taking levodopa
(one of them was on Duodopa) and 10 were taking dopaminergic
treatment other than levodopa (dopamine agonists and MAO
inhibitors). Mean LED was 469.9 mg/day ± 354. Mean UPDRS
III was 12.45± 6.9 points.
Gender
Comparing responses to probiotics in relation to gender, we
found a statistically significant difference between male and
female PD patients in ROS production from PBMCs. The effect
of LR06 was more pronounced in samples from male vs. female
donors (81 and 60% reduction compared to baseline levels,
respectively; p < 0.05; Table 4). On the contrary, BS01 was
more effective in samples from female than male patients (84
and 69% reduction compared to baseline levels, respectively;
p < 0.05; Table 4).
Disease Duration
We analyzed ROS and cytokine levels from PD-PBMCs exposed
to different probiotic strains in relation to disease duration.
We found that LA02 provided a robust anti-oxidant effect,
which decreased significantly in samples of patients with longer
disease duration (rho = 0.22, p < 0.05 Table 5, Figure 3). Such
correlation was not detected with other strains. Furthermore, we
found no other statistically significant correlation between the
effect of the different strains and the remaining clinical variables
(H&Y stage, UPDRS score, LED, data not shown).
DISCUSSION
In this study we showed that probiotic strains modulate the
release of cytokines and ROS by PBMCs of PD patients
and healthy controls. Particularly, L. salivarius (LS01) and L.
acidophilus (LA02) showed the best profiles in PD-PBMCs, being
able to significantly decrease all the pro-inflammatory cytokines
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TABLE 5 | Correlations between probiotic strains modulation of ROS production
and clinical characteristics of PD patients.
Probiotic
strain
Disease
duration
H&Y stage UPDRS III
score
LED
LA02 (rho; p) 0.22; 0.002 0.18; 0.94 0.04; 0.55 0.03; 0.22
LP01 0.05; 0.19 −0.03; 0.53 0.07; 0.53 −0.01; 0.60
LR06 0.08; 0.88 −0.08; 0.83 −0.16; 0.40 0.06; 0.80
LS01 0.17; 0.61 0.25; 0.55 0.28; 0.63 0.05; 0.12
BR03 −0.01; 0.83 0.08; 0.84 −0.10; 0.88 0.01; 0.73
BS01 −0.05; 0.45 0.32; 0.21 0.06; 0.33 0.14; 0.48
Data are expressed as the value after probiotic strain exposure from a baseline
conventionally established as 1. The statistically significant differences are shown in bold.
FIGURE 3 | Correlation between ROS production and disease duration for
probiotic LA02 (p = 0.002).
and increase the anti-inflammatory ones. The same strains were
also able to significantly reduce ROS production in both PD
and HD-PBMCs. In addition, all the tested probiotic strains
restored epithelial damage in Caco-2 cells. Finally, the tested
probiotic strains exerted a robust capacity of inhibiting E. coli
and K. pneumoniae. These Gram-negative bacteria are frequently
detected in blood cultures of septic PD patients (22). Such
antagonistic activity might be ascribed to the active bacteriocins
secreted by probiotic strains. Probiotics have been studied in PD
for their potential symptomatic effect on constipation (33) and
probiotic strains BS01, LP01, and BR03 have shown improvement
in constipation and associated symptoms in healthy adults (34)
and more interestingly in chronically constipated elderly (35).
However, despite the great interest that recently arose around
the gut-brain axis in health and disease, our study is the first
to specifically address the effect of probiotics on mediators
of inflammation and oxidative damage in PBMCs of PD
patients. On the other hand, experimental evidence on the anti-
inflammatory and anti-oxidative effects of probiotics is rapidly
growing. L. plantarum displayed the capacity of decreasing the
histopathological damages in a murine model of Alzheimer’s
disease (AD) leading to increased production of acetylcholine
with consequent clinical improvement (36). Accordingly, it was
shown that probiotics administration was effective in modulating
cognitive functions in a group of AD patients (37). Probiotics
may also be helpful in other contexts of neuroinflammation such
as post-traumatic stress disorder, amyotrophic lateral sclerosis
and cognitive dysfunction after surgery (38–40). Of note, in a
murine model of stress, modification of gut microbiota provided
both behavioral and immunological beneficial effects (41).
Altogether, such findings suggest that probiotics may
represent a promising strategy to counteract the detrimental
immune activation that takes place in PD. In fact, work by
independent groups is indicating that peripheral and central
immune responses are strictly interconnected in PD and the
study of such mechanisms may provide relevant advances in
both diagnostic and therapeutic areas (42, 43). An important
breakthrough in this area was the demonstration of the antigenic
role of α-syn on peripheral T cells: such epitopes can in fact
drive T helper and cytotoxic responses in PD patients (44).
Moreover, recent work by Kustrimovic et al. showed that PD
patients display a predominance of Th1 mediated responses
compared to healthy controls (45). A pro-inflammatory profile,
with increased production of IL-1α, IL-1β, and CXCL8 was also
detected in stool samples of PD patients, further supporting
the involvement of intestinal immunity in PD (46). The results
of the present study support the concept of a predominantly
pro-inflammatory environment in the periphery, since pro-
inflammatory cytokines production was significantly increased in
PD patients vs. controls. Notably, the probiotic strains tested in
our in vitro experiments were able to counterbalance such pro-
inflammatory response. Our results also suggest the involvement
of IL17A in PD: patients present in fact higher levels of IL17A
than healthy controls. The role of IL17 producing T helper cells
(Th17) in the context of neurodegeneration has not yet been
completely elucidated (47). There is evidence showing that Th17
cause cell death in a human iPSC-based model of PD and also
evidence that Th17 can be induced and regulated by the intestinal
microbiota (48, 49).
Our study has indeed some limitations: sample size is
relatively small, and the cross-sectional design suggests caution
in the interpretation of results. Furthermore, our data derive
from in vitro experiments, which might not reflect precisely
the complex pathophysiological dynamics of PD and should
therefore be reproduced in vivo. Possible strategies may involve
a study on an animal model of PD, or alternatively the direct
evaluation of the clinical and biological effects of probiotics
administration in PD patients. In both cases, a longitudinal
study in which biomarkers and clinical findings are collected
before and after probiotics administration would likely provide
important responses.
Our data also suggest that the effect of probiotics might be
different with respect to disease stage and gender. Accordingly,
we found that LA02 provided a down-modulation of ROS
that was more pronounced in the early stages of disease.
These data need further confirmation since previous studies
did not detect any correlations between clinical or biological
variables and disease stage in PD patients treated with probiotics
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(46). Moreover, LR06 and BS01 displayed different anti-
inflammatory and anti-oxidant activities in PBMCs from male
compared to female PD patients. Of note, it was previously
reported that microbiota composition may differ between male
and female subjects and that this in turn may influence
immune functions (50). One last open question regards the
relationships between probiotics, peripheral immune function
and dopaminergic therapy, especially considering that, to date,
the influence of PD treatment on peripheral immunity is
still controversial (51–53). Definite answers to this question,
as well as to whether and how probiotic administration
should be personalized, will likely come from longitudinal
in vivo studies.
Overall, our preliminary findings suggest a potential role
for probiotic strains in modulating inflammation and oxidative
stress and protecting the epithelium from gut permeability.
Further relevant findings include a possible inhibitory effect
against E. coli and K. pneumoniae, which might be exerted
without interfering with levodopa levels.
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